[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cirrhosis-alcoholic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cirrhosis-alcoholic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100628741","financial-rewards-for-reducing-alcohol-use-in-patients-with-liver-disease-100628741",false,"NCT07465588","Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease","Randomized Evaluation of Incentives FOR Clinical Effectiveness in Liver Recovery (REINFORCE Trial): A PEth-Based Contingency Management Pilot Randomized Controlled Trial for Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease","REINFORCE","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of alcohol use disorder based on DSM 5 criteria\n* Diagnosis of alcohol associated liver disease or clinically suspected alcohol related liver injury\n* Evidence of recent alcohol use or at risk for alcohol relapse\n* Receiving care in hepatology or liver disease clinic at the participating institution\n* Willingness to undergo serial phosphatidylethanol (PEth) testing using dried blood spot samples\n* Ability to provide informed consent\n* Willingness to participate in the contingency management intervention and follow study procedures\n\nExclusion Criteria:\n\n* Severe cognitive impairment or medical condition that prevents participation in study procedures\n* Active psychosis or severe psychiatric instability that would interfere with participation\n* Current enrollment in another contingency management program targeting alcohol use\n* Medical instability requiring hospitalization at the time of enrollment\n* Inability to communicate in English (if study materials are only available in English)\n* Any condition that, in the opinion of the investigators, would make participation unsafe or interfere with completion of the study","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking. The blood test is called phosphatidylethanol (PEth), which can detect alcohol use over the past three to four weeks. The financial reward program is called contingency management (CM).\n\nThe study has two parts. Part 1 involves one-time interviews and surveys with patients and healthcare providers to understand how a PEth-based CM program could best be delivered in a liver disease clinic. Part 2 is a pilot randomized controlled trial (the REINFORCE Trial) in which participants are randomly assigned to one of two groups: (1) a rewards group that receives escalating financial incentives when PEth results show reduced or no alcohol use, or (2) a monitoring group that receives fixed payments regardless of PEth results. Both groups receive PEth testing and continue their usual medical care. The study will assess whether the rewards program improves alcohol abstinence and reduction at 12 and 24 weeks.'",[27,28,29,30],"Alcohol Use Disorder","Alcohol-associated Liver Disease","Liver Cirrhosis, Alcoholic","Alcohol-Associated Hepatitis",[32,33,34,35,36,37,38,39,40,41],"Contingency Management","Phosphatidylethanol","PEth","Dried Blood Spot","Alcohol Biomarker","Alcohol Abstinence","Hepatology","Liver Disease","Financial Incentives","Behavioral Intervention","NOT_YET_RECRUITING","2026-03-10",{"date":45,"type":46},"2026-03-12","ACTUAL",{"date":48,"type":21},"2026-08-01",{"date":50,"type":21},"2028-06-30",{"name":52,"class":53},"Massachusetts General Hospital","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100584492","phase-2-a-tango-phase-2-study-100584492","NCT06890039","A-TANGO Phase 2 Study","Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects With (sAH) and (ACLF)","A-TANGO","Inclusion Criteria:\n\n* Patients accepted for inclusion into the study must meet all of the following criteria:\n\n  1. Male and female subjects ≥18 of age and ≤75 years of age\n  2. Compliance with acceptable contraceptive methods.\n  3. With a diagnosis of severe alcoholic hepatitis that is resistant to steroid therapy as defined by a Lille score of \\>0.45 and\u002For in whom steroids are contraindicated.\n  4. Eligible subjects will have Grade 1-3 ACLF with a maximum of three organ failures using the CLIF-C OF score AND the CLIF-C ACLF-CRP score of \\>35 and \\\u003C60.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria are to be excluded:\n\n  * Refusal to give informed consent\n  * Mechanical ventilation due to respiratory failure and\u002For need for renal replacement therapy and or requiring inotropes for circulatory support with a noradrenaline requirement of \\>0.5ug\u002Fkg\u002Fmin to maintain mean arterial pressure \\> 70mmHg\n  * Subject has received any investigational drug within 30 days of randomization\n  * Subject has any of the following conditions:\n\n    * history of liver transplantation\n    * postoperative decompensation after partial hepatectomy\n    * liver failure without underlying chronic liver injury\n  * Any untreated infections (\\\u003C48h antibiotic therapy) including gram-positive infections, active tuberculosis or coinfection with HIV.\n  * Chronic or pre-existing kidney failure, survival prognosis of \\\u003C6 months due to severe co-morbid conditions that might confound study results or compromise subject safety\n  * Methemoglobinemia, clinically-significant disseminated intravascular coagulation, uncontrolled bleeding, sickle cell anemia\n  * Uncontrolled seizures, Creutzfeldt-Jakob disease, glucose-6-phosphate dehydrogenase deficiency.\n  * Active malignancy, premalignant hematological disorders (e.g., myelodysplastic syndrome, chronic myeloid leukemia) or multiorgan failure (≥ 4 organ failures).\n  * Pregnancy or nursing women\n  * Allergy to eggs","75 Years",{"count":64,"type":21},78,[66],"PHASE2","The purpose of this research is to know if a new combination of drugs (TAK-242 and G-CSF) in combination with standard therapy for acute-on-chronic liver failure (ACLF) is more effective than standard therapy for ACLF treatment and is safe.\n\nDescription of the population to be studied: ACLF is a syndrome that occurs in patients with chronic liver disease, with or without previously diagnosed cirrhosis, which is characterized by acute hepatic decompensation. Cirrhosis is a chronic disease of the liver marked by degeneration of cells, inflammation, and thickening and scarring (fibrosis) of liver tissue. Hepatic decompensation is a sudden decline in liver function. It is characterized by severe liver damage and complications like jaundice (yellowing of the skin or whites of the eyes), ascites (a condition where excess fluid accumulates in the abdominal cavity and in abdominal organs) and encephalopathy (a group of symptoms that result from damage or dysfunction in the brain, causing a range of cognitive and neurological impairments). It may result in liver failure, one or more organ failures other than liver (renal, brain, coagulation, respiratory, cardiovascular), and is associated with increased mortality within 28-days and up to 3 months from onset. Grade 1 ACLF has a \\>15% risk of mortality at 28 days.\n\nPurpose of the study: The investigational medication, TAK-242, is aimed at stopping an \"over-reaction\" of the immune system (the body's defense system) while G-CSF encourages your liver cells to grow. In patients with severe inflammation of the liver due to alcohol \\[severe alcoholic hepatitis (sAH)\\] and ACLF, this over-reaction may cause the liver and other organs in the body to suddenly stop working (organ failure). The hypothesis of the study is that by blocking this over-reaction and encouraging your liver cells to grow your condition may improve.",[69,70,29],"Acute-On-Chronic Liver Failure","Alcoholic Hepatitis",[72,73,74,75],"Novel combinatorial therapy","Improve hepatocyte proliferation","ACLF","Liver disease","2025-07-23",{"date":78,"type":46},"2025-07-29",{"date":80,"type":21},"2025-09-01",{"date":82,"type":21},"2026-12-31",{"name":84,"class":85},"Yaqrit Ltd","INDUSTRY",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100578722","acquisition-of-cardiac-function-parameters-in-mri-and-echocardiography-in-patients-with-ethyltoxic-liver-cirrhosis-and-transjugular-intrahepatic-portosystemic-shunt-tipss-placement-100578722","NCT06814990","Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement","Erfassung Kardialer Funktionsparameter in MRT Und Echokardiographie Bei Patienten Mit Ethyltoxischer Leberzirrhose Und Transjugulärer Intrahepatischer Portosystemischer Shunt (TIPSS)-Anlage","EVALUATION","Inclusion Criteria:\n\n* Age 18 to 99 years\n* Written informed consent of the patient\n* Decompensated liver cirrhosis, defined by clinical, imaging or laboratory criteria\n* Patient receives an elective TIPSS in the appropriate clinical context at the JUH\n\nExclusion Criteria:\n\n* Pregnancy\n* Implants not suitable for magnetic resonance imaging\n* Medical\u002Fpersonal reasons against magnetic resonance imaging (claustrophobia, patient cannot lie flat or follow breathing commands)\n* Patient in critical condition or incompliant","99 Years",{"count":96,"type":21},80,[24],"The aim of this clinical trial is to investigate the development of cardiac decompensation following transjugular intrahepatic portosystemic shunt (TIPSS) implantation in order to draw conclusions for future treatment methods or exclusion criteria prior to TIPS implantation.\n\nThe main questions to be answered are:\n\nHow often do symptoms of cardiac decompensation develop over a one year period? What laboratory, clinical or imaging morphological changes are associated with this? In addition to the standardised clinical procedure for TIPSS implantation, participants will undergo 3 cardiac magnetic resonance imaging (MRI), extended echocardiographic examinations (both just before, 3 days after and 3 months after implantation) and laboratory chemistry tests for specific endothelial and inflammatory markers (just before, on the day of implantation, 1 day after, 1, 3, 6 and 12 months after implantation).",[100,29,101,102,103],"MASLD","Cirrhosis of Liver","Heart Decompensation","TIPS",[105,106,103],"Chirrotic cardiomyopathy","Liver chirrosis","RECRUITING","2025-02-11",{"date":110,"type":46},"2025-02-13",{"date":112,"type":46},"2024-04-19",{"date":114,"type":21},"2027-04-19",{"name":116,"class":53},"Stephanie Gräger",1]